A detailed history of Advisor Group Holdings, Inc. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 663 shares of URGN stock, worth $10,528. This represents 0.0% of its overall portfolio holdings.

Number of Shares
663
Previous 663 -0.0%
Holding current value
$10,528
Previous $9,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

SELL
$10.87 - $15.93 $5,902 - $8,649
-543 Reduced 45.02%
663 $9,000
Q3 2023

Nov 13, 2023

BUY
$8.84 - $22.64 $5,180 - $13,267
586 Added 94.52%
1,206 $16,000
Q1 2023

May 12, 2023

SELL
$7.99 - $11.02 $159 - $220
-20 Reduced 3.13%
620 $5,000
Q4 2022

Feb 10, 2023

BUY
$7.55 - $11.9 $151 - $238
20 Added 3.23%
640 $5,000
Q2 2022

Aug 10, 2022

BUY
$5.12 - $8.74 $614 - $1,048
120 Added 24.0%
620 $5,000
Q1 2022

May 04, 2022

BUY
$5.92 - $9.73 $2,960 - $4,865
500 New
500 $4,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $361M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.